ImmunoVaccine Technologies Inc. Completes Scale-Up of VacciMax to Commercially Relevant Scale
IVT's product, VacciMax(R), is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare VacciMax(R) for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements including manufacturing in a GMP setting. The ability to scale-up, under GMP or good manufacturing practices, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax(R) at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.
IVT's testing verified that development batches produced at Dalton at an increasing scale retained their expected biological activity. Analytical testing also showed that the various elements of the platform are chemically stable. The latest batch produced at the 50 litre scale also met manufacturing and chemical specifications.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.